These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19966089)

  • 1. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis.
    Pavy S; Toonen EJ; Miceli-Richard C; Barrera P; van Riel PL; Criswell LA; Mariette X; Coenen MJ
    Ann Rheum Dis; 2010 Jun; 69(6):1022-8. PubMed ID: 19966089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis.
    Zeng Z; Duan Z; Zhang T; Wang S; Li G; Gao J; Ye D; Xu S; Xu J; Zhang L; Pan F
    Mod Rheumatol; 2013 May; 23(3):489-95. PubMed ID: 22760475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis.
    Swierkot J; Bogunia-Kubik K; Nowak B; Bialowas K; Korman L; Gebura K; Kolossa K; Jeka S; Wiland P
    Joint Bone Spine; 2015 Mar; 82(2):94-9. PubMed ID: 25311255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Rho YH; Choi SJ; Ji JD; Song GG
    Rheumatol Int; 2006 Dec; 27(2):157-61. PubMed ID: 16909270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis.
    Toonen EJ; Barrera P; Fransen J; de Brouwer AP; Eijsbouts AM; Miossec P; Marotte H; Scheffer H; van Riel PL; Franke B; Coenen MJ
    Arthritis Res Ther; 2012 Dec; 14(6):R264. PubMed ID: 23217265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis.
    Radstake TR; Fransen J; Toonen EJ; Coenen MJ; Eijsbouts AE; Donn R; van den Hoogen FH; van Riel PL
    Ann Rheum Dis; 2007 Nov; 66(11):1525-30. PubMed ID: 17456524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis.
    O'Rielly DD; Roslin NM; Beyene J; Pope A; Rahman P
    Pharmacogenomics J; 2009 Jun; 9(3):161-7. PubMed ID: 19365401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.
    Bek S; Bojesen AB; Nielsen JV; Sode J; Bank S; Vogel U; Andersen V
    Pharmacogenomics J; 2017 Oct; 17(5):403-411. PubMed ID: 28607508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
    Mugnier B; Balandraud N; Darque A; Roudier C; Roudier J; Reviron D
    Arthritis Rheum; 2003 Jul; 48(7):1849-52. PubMed ID: 12847678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.
    Miceli-Richard C; Comets E; Verstuyft C; Tamouza R; Loiseau P; Ravaud P; Kupper H; Becquemont L; Charron D; Mariette X
    Ann Rheum Dis; 2008 Apr; 67(4):478-84. PubMed ID: 17673491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update.
    Lee YH; Ji JD; Bae SC; Song GG
    J Rheumatol; 2010 Apr; 37(4):740-6. PubMed ID: 20194454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment.
    Tan RJ; Gibbons LJ; Potter C; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; ; Barton A
    Ann Rheum Dis; 2010 Jun; 69(6):1029-35. PubMed ID: 20444755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.